Go Back

Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1

Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1

ddPCR Test Measures mRNA Expressions from Immune and Cancer Cells


Poster Title: Development of ddPCR blood-based diagnostic tests that simultaneously measure mRNA expression from immune and cancer cells.


Poster Session Date/Time: February 24, 11:30AM – 1:00PM; 5:30PM-6:30PM


Presenting Author: Hestia Mellert, Ph.D

Corresponding Author: Gary Pestano, Ph.D


Location: Regency Ballroom, Hyatt Regency Orlando, 9801 International Dr, Orlando, FL

About Biodesix

Biodesix® is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic liquid biopsy tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests and with the Biodesix Lung Reflex™ testing strategy, for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of personalized medicine, Biodesix is developing new tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.


Topics: ddPCR, Press Releases, liquid biopsy, mRNA, PD-L1